These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26146944)

  • 1. Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?
    Ramjaun A; AlDuhaiby E; Ahmed S; Wang L; Yu E; Nathan PC; Hodgson DC
    Pediatr Blood Cancer; 2015 Dec; 62(12):2197-203. PubMed ID: 26146944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors.
    Abosoudah I; Greenberg ML; Ness KK; Benson L; Nathan PC
    Pediatr Blood Cancer; 2011 Sep; 57(3):467-72. PubMed ID: 21280201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
    Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
    Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yield of screening echocardiograms during pediatric follow-up in survivors treated with anthracyclines and cardiotoxic radiation.
    Spewak MB; Williamson RS; Mertens AC; Border WL; Meacham LR; Wasilewski-Masker KJ
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27966803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is screening for abnormal ECG patterns justified in long-term follow-up of childhood cancer survivors treated with anthracyclines?
    Pourier MS; Mavinkurve-Groothuis AM; Loonen J; Bökkerink JP; Roeleveld N; Beer G; Bellersen L; Kapusta L
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Echocardiography as Screening for Late-onset Anthracycline-induced Cardiotoxicity in Pediatric Cancer Survivors: Observations from the First Decade After End of Therapy.
    Moke DJ; Schubert LE; Sun HY; Printz BF; Dietz AC
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e283-e288. PubMed ID: 29432303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing anthracycline-treated childhood cancer survivors with advanced stress echocardiography.
    Ryerson AB; Border WL; Wasilewski-Masker K; Goodman M; Meacham L; Austin H; Mertens AC
    Pediatr Blood Cancer; 2015 Mar; 62(3):502-8. PubMed ID: 25393686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.
    Leger K; Slone T; Lemler M; Leonard D; Cochran C; Bowman WP; Bashore L; Winick N
    Pediatr Blood Cancer; 2015 Jan; 62(1):123-7. PubMed ID: 25176022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.
    Toro-Salazar OH; Gillan E; O'Loughlin MT; Burke GS; Ferranti J; Stainsby J; Liang B; Mazur W; Raman SV; Hor KN
    Circ Cardiovasc Imaging; 2013 Nov; 6(6):873-80. PubMed ID: 24097420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.
    Mladosievicova B; Urbanova D; Radvanska E; Slavkovsky P; Simkova I
    J Exp Clin Cancer Res; 2012 Oct; 31(1):86. PubMed ID: 23057994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study.
    van der Pal HJ; van Dijk IW; Geskus RB; Kok WE; Koolen M; Sieswerda E; Oldenburger F; Koning CC; van Leeuwen FE; Caron HN; Kremer LC; van Dalen EC
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):213-22. PubMed ID: 25442333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center.
    Watts RG; George M; Johnson WH
    Cancer; 2012 Apr; 118(7):1919-24. PubMed ID: 21882180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
    Hudson MM; Rai SN; Nunez C; Merchant TE; Marina NM; Zalamea N; Cox C; Phipps S; Pompeu R; Rosenthal D
    J Clin Oncol; 2007 Aug; 25(24):3635-43. PubMed ID: 17704413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echocardiographic evaluation of patients cured of childhood cancer: a single center study of 117 subjects who received anthracyclines.
    Bossi G; Lanzarini L; Laudisa ML; Klersy C; Raisaro A; Aricò M
    Med Pediatr Oncol; 2001 Jun; 36(6):593-600. PubMed ID: 11344489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
    Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
    Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insight into the intraventricular pressure gradient as a sensitive indicator of diastolic cardiac dysfunction in patients with childhood cancer after anthracycline therapy.
    Shigemitsu S; Takahashi K; Yazaki K; Kobayashi M; Yamada M; Akimoto K; Tamaichi H; Fujimura J; Saito M; Nii M; Itatani K; Shimizu T
    Heart Vessels; 2019 Jun; 34(6):992-1001. PubMed ID: 30673819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors.
    De Caro E; Smeraldi A; Trocchio G; Calevo M; Hanau G; Pongiglione G
    Pediatr Blood Cancer; 2011 Jan; 56(1):122-6. PubMed ID: 21058389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.
    Armstrong GT; Joshi VM; Ness KK; Marwick TH; Zhang N; Srivastava D; Griffin BP; Grimm RA; Thomas J; Phelan D; Collier P; Krull KR; Mulrooney DA; Green DM; Hudson MM; Robison LL; Plana JC
    J Am Coll Cardiol; 2015 Jun; 65(23):2511-22. PubMed ID: 26065990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.
    Armenian SH; Gelehrter SK; Vase T; Venkatramani R; Landier W; Wilson KD; Herrera C; Reichman L; Menteer JD; Mascarenhas L; Freyer DR; Venkataraman K; Bhatia S
    Clin Cancer Res; 2014 Dec; 20(24):6314-23. PubMed ID: 24947931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.